|
GSK starts final-stage tests on severe asthma drug
Reuters Severe refractory asthma only affects around 4 percent of patients with the disease, so the drug may not become a major seller for GSK but could consolidate the group's strong grip on the market for lung drugs. (Reporting by Ben Hirschler). Health … GSK Begins Phase lll Program for Mepolizumab in Severe Refractory Asthma |
View full post on asthma – Google News